OSTEOCOOL™ RF ABLATION for the treatment of painful bone tumors
See Clinical Evidencelatest news
SIR 2021 ABSTRACT OF THE YEAR
The OsteoCool™ Post Market Clinical Study (OPuS One) is a multicenter study collecting real-world evidence on the efficacy and safety of OsteoCool™ RF ablation.
Twelve-month data show outcomes in 206 patients treated with OsteoCool™ RF ablation, as well as pain relief and improved quality of life in as soon as three days.1
Product Overview
The OsteoCool™ RF ablation system is cooled radiofrequency ablation technology. It offers simultaneous, dual-probe capabilities for treating painful bone tumors, including benign and painful metastatic lesions. The system’s algorithms are designed to perform optimally in bone, allowing you to overcome challenges through a wide range of ablation scenarios, letting you treat patients confidently and consistently.
Intro to OsteoCool™ RF Ablation System Animation
More information (see more)
Less information (see less)
For Oncologists
See physician videos about using OsteoCool™ RF ablation for cancer patients.
Indications, Safety, and Warnings
INDICATIONS
- Intended for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body
- Coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy
- Ablation of benign bone tumors such as osteoid osteoma
RISKS
- As a consequence of electrosurgery, damage to surrounding tissue through iatrogenic injury could occur
- Pulmonary embolism
1
Levy J, David E, Hopkins T, et al. Improvement in Quality of Life on Patients Treated for Painful Osseous Metastases With Radiofrequency Ablation: The Opus One Study, abstract presented at Society for Interventional Radiology Annual Scientific Meeting, March 20-26, 2021, virtual. https://www.researchgate.net/publication/351170997_Abstract_No_78_Improvement_in_quality_of_life_in_patients_treated_for_painful_osseous_metastases_with_radiofrequency_ablation_the_OPuS_One_study. Accessed November 8, 2021.